Physician profile
Vanessa Cloud
NPI 1053961250
$10,929.79
in general payments reported to CMS, 2019-2025
24 companies · $3,289 in 2025
The $3,289 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $212 · 2022: $2,254 · 2023: $2,220 · 2024: $2,955 · 2025: $3,289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,145 · Education: $189 · Travel and Lodging: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,145.36 |
| Education | $189.00 |
| Travel and Lodging | $129.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,594.84 | 2021-2025 | |
| Amgen INC. | $2,328.82 | 2021-2025 | Krystexxa, Enbrel, Evenity |
| Janssen Biotech, INC. | $1,240.76 | 2021-2025 | Tremfya, Simponi Aria |
| Pfizer INC. | $720.11 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $632.25 | 2021-2025 | |
| Horizon Therapeutics Plc | $546.82 | 2022-2023 | Krystexxa |
| Lilly USA, LLC | $453.23 | 2022-2024 | Taltz |
| Ucb, INC. | $369.21 | 2022-2025 | Cimzia, Bimzelx |
| Astrazeneca Pharmaceuticals Lp | $314.67 | 2022-2025 | Evusheld |
| Radius Health, INC. | $289.39 | 2022-2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $203.95 | 2022-2025 | Orencia |
| Glaxosmithkline, LLC. | $187.81 | 2022-2025 | Benlysta |
| Genentech USA, INC. | $179.75 | 2022-2025 | Actemra, Gazyva |
| Genzyme Corporation | $158.67 | 2024-2025 | |
| Kyowa Kirin, INC. | $135.83 | 2024 | Crysvita |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $135.53 | 2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.90 | 2021-2024 | Ofev |
| Neurocrine Biosciences, INC. | $126.36 | 2024 | Ingrezza |
| Fresenius Kabi USA, LLC | $53.97 | 2025 | Tyenne |
| Mallinckrodt Hospital Products INC. | $34.72 | 2025 | Acthar |
| Almatica Pharma LLC | $28.41 | 2025 | Teriparatide |
| Alexion Pharmaceuticals, INC. | $24.63 | 2024 | Strensiq |
| Invivyd INC | $24.00 | 2025 | Pemgarda |
| Ferring Pharmaceuticals INC. | $19.16 | 2024 | Euflexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Cloud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.